Conatus Pharmaceuticals (NASDAQ:CNAT)

CAPS Rating: 5 out of 5

Caps

How do you think CNAT will perform against the market?

Add Stock to CAPS Watchlist

All Players

46 Outperform
4 Underperform
 

All-Star Players

10 Outperform
1 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top CNAT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.84)
Submitted October 03, 2016

After nine years on CAPS and having written over 2000 pitches I no longer feel obligated to write pitches on my picks. Part of this is because I'm pulling back from time spent on studying stocks. I've acquired a wife and three children since 2007,… More

sinvestor (53.10)
Submitted January 14, 2014

Really???

CNAT VS S&P 500 (SPY)

CNAT Summary

Fools bullish on CNAT are also bullish on:

Fools bearish on CNAT are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CNAT.

Recs

0
Member Avatar marsuculix (34.78) Submitted: 12/20/2016 1:56:02 AM : Outperform Start Price: $5.07 CNAT Score: -35.48

now collaboration with Novartis for NASH looks profitable...

Recs

6
Member Avatar zzlangerhans (99.84) Submitted: 10/3/2016 5:01:59 PM : Outperform Start Price: $1.96 CNAT Score: +85.13

After nine years on CAPS and having written over 2000 pitches I no longer feel obligated to write pitches on my picks. Part of this is because I'm pulling back from time spent on studying stocks. I've acquired a wife and three children since 2007, and they need my time more than they need more money. However, the main reason is that CAPS administrators no longer respond to my notifications regarding ticker changes, reverse splits, unlisted stocks, bugs, etc. If they can't be bothered to maintain the site any more, I can't be bothered to write pitches. I'll still write some now and then if I have nothing better to do.

I don't like much about Conatus, and I've done well with red thumbing them on every rise over the last year. However, the NASH landscape has changed once again thanks to the shocking Tobira acquisition by Allergan at a 700%+ premium. This has more significant implications for the NASH crew than the Intercept effect of early 2014. Positive data for Intercept had little read through to the other NASH stocks yet it provided a lasting boost to their share prices, even as Intercept quickly slipped backwards. The Tobira acquisition doesn't mean that big pharma will suddenly start hunting for other small NASH companies, but it does have a stronger read through than a trial result. One recent example would be hepatitis C companies. Once one got bought out, three or four others went in fairly rapid succession at high premiums. Vetting was clearly lacking, as BMS got taken to the tune of two billion buying out Inhibitex and their toxic candidate.

It doesn't make sense to buy NASH stocks blindly. Galectin is the sorriest of the bunch and the Tobira buyout didn't stop them from collapsing on their latest trial failure (although its share price is starting to look interesting again). Conatus has slipped back towards the level seen before the Tobira buyout and they don't have any important trial data expected in the near future. For stocks like Conatus, that's a good thing. If Tobira was an isolated event then Conatus isn't likely to decline too much further. On the other hand, with even a small chance that another bull shark is looking for a little fish to swallow, Conatus has a potential for huge gains.

Recs

0
Member Avatar oscillation (75.16) Submitted: 1/16/2016 11:28:48 AM : Outperform Start Price: $1.70 CNAT Score: +100.19

nev

Leaderboard

Find the members with the highest scoring picks in CNAT.

Score Leader

slingermoonsine

slingermoonsine (72.71) Score: +249.66

The Score Leader is the player with the highest score across all their picks in CNAT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
MusicMoney88 < 20 1/13/2014 Underperform 3Y $12.92 -68.81% +41.52% +110.33 0 Comment
kayakmastr 94.63 1/13/2014 Underperform 1Y $12.92 -68.81% +41.52% +110.33 0 Comment
sinvestor 53.10 1/14/2014 Underperform 3Y $12.16 -66.86% +42.63% +109.49 1 Comment
oscillation 75.16 1/19/2016 Outperform 5Y $1.70 +137.06% +36.87% +100.19 1 Comment
TruffelPig < 20 3/1/2016 Outperform 5Y $1.80 +123.89% +33.32% +90.57 0 Comment
saab93boi < 20 1/5/2015 Underperform 5Y $10.00 -59.70% +28.49% +88.19 0 Comment
zzlangerhans 99.84 10/3/2016 Outperform 1Y $1.96 +105.61% +20.48% +85.13 3 Comments
dpid 87.49 10/12/2016 Outperform 3M $1.97 +104.57% +21.72% +82.84 0 Comment
portefeuille 98.77 10/5/2016 Outperform 5Y $2.08 +94.22% +20.32% +73.90 0 Comment
Playa15 < 20 4/6/2016 Outperform 5Y $3.07 +31.27% +26.69% +4.58 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackRothCapital 72.12 3/7/2014 Outperform NS $12.52 -67.81% +37.66% -105.47 0 Comment
TrackStifel 93.72 8/19/2013 Outperform NS $9.50 -57.58% +56.96% -114.54 0 Comment

Featured Broker Partners